MENU
NVS
Stock ticker: NYSE
PRICE
CHANGE
CAPITALIZATION

NVS stock forecast, quote, news & analysis

Novartis develops and manufactures innovative drugs... Show more

NVS
Daily Signal:
Gain/Loss:
A.I.Advisor
published price charts
A.I.Advisor
a Summary for NVS with price predictions
Aug 26, 2026

NVS in +2.43% Uptrend, growing for three consecutive days on August 18, 2026

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where NVS advanced for three days, in of 337 cases, the price rose further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on August 18, 2026. You may want to consider a long position or call options on NVS as a result. In of 80 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for NVS just turned positive on August 19, 2026. Looking at past instances where NVS's MACD turned positive, the stock continued to rise in of 44 cases over the following month. The odds of a continued upward trend are .

NVS moved above its 50-day moving average on August 18, 2026 date and that indicates a change from a downward trend to an upward trend.

Bearish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where NVS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

NVS broke above its upper Bollinger Band on August 19, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 61, placing this stock better than average.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.210) is normal, around the industry mean (19.339). P/E Ratio (23.798) is within average values for comparable stocks, (33.297). Projected Growth (PEG Ratio) (3.596) is also within normal values, averaging (11.241). Dividend Yield (0.030) settles around the average of (0.027) among similar stocks. P/S Ratio (5.356) is also within normal values, averaging (4.239).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. NVS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

A.I.Advisor
published Dividends

NVS paid dividends on March 16, 2026

Novartis AG NVS Stock Dividends
А dividend of $4.74 per share was paid with a record date of March 16, 2026, and an ex-dividend date of March 11, 2026. Read more...
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), ABBVIE (NYSE:ABBV), Merck & Co (NYSE:MRK), AstraZeneca PLC (NYSE:AZN), Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Pfizer (NYSE:PFE), Bristol-Myers Squibb Co (NYSE:BMY), Biogen (NASDAQ:BIIB).

Industry description

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

Market Cap

The average market capitalization across the Pharmaceuticals: Major Industry is 205.23B. The market cap for tickers in the group ranges from 72.83K to 1.06T. LLY holds the highest valuation in this group at 1.06T. The lowest valued company is CRXTQ at 72.83K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Major Industry was -1%. For the same Industry, the average monthly price growth was 3%, and the average quarterly price growth was 6%. NSRX experienced the highest price growth at 5%, while LLY experienced the biggest fall at -7%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Major Industry was -46%. For the same stocks of the Industry, the average monthly volume growth was -12% and the average quarterly volume growth was -35%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 26
P/E Growth Rating: 56
Price Growth Rating: 37
SMR Rating: 55
Profit Risk Rating: 61
Seasonality Score: -37 (-100 ... +100)
View a ticker or compare two or three
NVS
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

a manufacturer of health care and nutritional products

Industry PharmaceuticalsMajor

Profile
Details
Industry
Pharmaceuticals Major
Address
Lichtstrasse 35
Phone
+41 613241111
Employees
76057
Web
https://www.novartis.com
NVS in +2.43% Uptrend, growing for three consecutive days on August 18, 2026